Catalyst Event
Pfizer Inc (PFE) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/24/2026, 12:00:00 AM
Pfizer and partner Valneva announced on March 24, 2026, their intention to seek regulatory approval for their Lyme disease vaccine candidate (VLA15/PF-07307405) following positive Phase 3 trial results showing over 70% efficacy. This is estimated to have a medium impact as it addresses a significant unmet medical need.
Korean Translation
화이자와 파트너사 발네바는 2026년 3월 24일, 3상 임상시험에서 70% 이상의 효능을 보인 라임병 백신 후보물질(VLA15/PF-07307405)에 대한 규제 승인을 추진할 것이라고 발표함. 미충족 의료 수요가 높은 분야로 상당한 시장 영향이 예상됨.
Related Recent Events
Novo Nordisk A/S (NVO) · Other
Announced on Feb 24, 2026, that it will lower the U.S. list prices of key drugs Wegovy and Ozempic by approximately 50% and 35% respectively, effective January 1, 2027, to improve patient access.
1/1/2027, 12:00:00 AM
Novartis AG (NVS) · Other
Results from the Phase III Lp(a)HORIZON study of cardiovascular candidate pelacarsen are scheduled for 2026-06-30; this key clinical readout is estimated to have a >5% price impact expected.
6/30/2026, 12:00:00 AM
RELX PLC (RELX) · Other
Ex-dividend date for the 48.0 pence per share final dividend for fiscal year 2025 on May 7, 2026; dividend-related price adjustments are typically low, scheduled
5/7/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM
Leidos Holdings Inc (LDOS) · Earnings Release
Leidos is scheduled to release Q1 2026 financial results on May 5, 2026, with analysts forecasting EPS of $2.91-$2.94 expected.
5/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer's Q1 2026 earnings release is scheduled for May 5, 2026, scheduled.
5/5/2026, 12:00:00 AM